Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?

Our plain-English summary of Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?, by N. van Zandwijk, G. Reid, A. Linton, et al (Annals of Cardiothoracic Surgery, 2012).

The study

• Authors: N. van Zandwijk, G. Reid, A. Linton, S. Kao
• Journal: Annals of Cardiothoracic Surgery
• Published: 2012;1(4):481-6
• Cited by: 3 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

In plain English

This article was a perspective, an opinion and review piece with no new patient data. It discussed published research on radical surgery for malignant pleural mesothelioma (MPM), mainly extrapleural pneumonectomy (EPP), and on choosing patients for it. Asbestos appeared only in the introduction, which tied past and rising asbestos use to a growing MPM epidemic and called inflammation from inhaled fibers the principal cause, assumed to take 20 to 60 years to produce disease. Among earlier work, they described a first surgical series with hospital mortality around 30%, and later multimodality reports with mortality of 6% or less. They also described the UK MARS feasibility study, where perioperative mortality in the EPP arm was 18%, and argued its conclusion was hard to generalize beyond the participating centres. They reviewed prognostic factors including histologic subtype, lymph node involvement, the neutrophil-to-lymphocyte ratio and PET scanning, and called for prospective validation of the last two. The authors concluded that multimodality therapy should be offered only to carefully selected patients, that referral to experienced centres is reasonable, and that a new randomized trial will not settle the EPP debate.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Perspective (narrative opinion and review article); no original data collected
• Who was studied: No patients were studied directly; the article discussed published studies of patients with malignant pleural mesothelioma considered for radical surgery
• Exposure: Asbestos exposure was not studied. In the introduction, the authors linked past and rising asbestos use and the presence of asbestos-containing materials to an increasing MPM epidemic. They called chronic inflammation from inhaled asbestos fibers the principal cause, assumed to take 20-60 years (median around 40 years) before disease appears, which explains diagnosis at older ages. No fiber types were named. The article's subject was treatment: radical surgery (EPP, pleurectomy and decortication) within multimodality therapy
• Main results:
  • Reported by the authors from earlier work (not this article's own data): hospital mortality in Butchart's first series of EPP patients was around 30%
  • Reported by the authors from earlier work: several reports in which EPP formed part of multimodality treatment documented mortality rates of 6% or less
  • Reported by the authors from earlier work: in the UK MARS feasibility study (50 patients from 12 centres randomly assigned to EPP or no EPP), perioperative mortality in the EPP arm was 18%. The authors argued that this study's conclusion was difficult to generalize to other centres
  • Reported by the authors from earlier work: thorough preoperative staging showed that 26% of MPM patients were ineligible for radical treatment
  • The authors stated that the main challenge is to prospectively validate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and PET scanning in MPM
• The authors' conclusion: The authors concluded that multimodality therapy for MPM should be offered only to carefully selected patients, that it is reasonable to encourage referral of MPM patients to centres with expertise, and that the debate about EPP will not be solved by renewed efforts to obtain an answer from a randomized study

Topics

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma.

Related studies

• The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma — A. Nakas, D. Waller, et al. (2012)
• Does Simian Virus 40 (SV40) Have a Role in UK Malignant Pleural Mesothelioma? No Role is Identified in a Sensitive RNA In Situ Hybridization Study on Potentially Affected Birth Cohorts — F.S. Alchami, R.L. Attanoos, et al. (2020)
• Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy — G. Glockzin, H.J. Schlitt, et al. (2009)
• Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations — L.M. Enomoto, P. Shen, et al. (2019)
• Should all patients who have mesothelioma diagnosed by video-assisted thoracoscopic surgery have their intervention sites irradiated? — M. Nagendran, A. Pallis, et al. (2011)
• A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy — J.M. Baumgartner, T.G. Kwong, et al. (2016)

Browse return to medical research.